Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

Archives of Pathology and Laboratory Medicine - United States
doi 10.5858/arpa.2018-0043-oa
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Archives of Pathology and Laboratory Medicine

Related search

Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-Naive Programmed Death Ligand 1–Positive Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Expression of Programmed Cell Death-Ligand 1 and Its Correlation With Clinical Outcomes in Gliomas

Oncotarget
Oncology
2016English

Clinicopathological Significance and Prognostic Implication of Programmed Death-1 Ligand 2 Expression in Colorectal Cancer

International Journal of Biological Markers
OncologyCancer ResearchClinical BiochemistryForensic MedicineMedicinePathology
2019English

Topotecan Decreases the Expression of Programmed Death-Ligand 1 in Glioblastoma Cell Lines; Implications for Immunotherapy

Matters
2017English

Pembrolizumab as First-Line Therapy in Programmed Death Ligand 1-Positive Advanced Lung Cancer: Is It as Effective as We Think It Is?

Cancer
Cancer ResearchOncology
2017English

Programmed Death-Ligand 1 Expression and Its Correlation With Clinicopathological Parameters in Gallbladder Cancer

Journal of Pathology and Translational Medicine
Forensic MedicinePathologyHistology
2020English

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors

Frontiers in Oncology
Cancer ResearchOncology
2019English

MicroRNAs Aid the Assessment of Programmed Death Ligand�1 Expression in Patients With Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2019English

Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma

Journal of Cancer
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy